FDA Approves Lifileucel, the First Cellular Therapy for Unresectable or Metastatic Melanoma
The U.S Food and Drug Administration (FDA) has approved lifileucel (Amtagvi, Iovance Biotherapeutics Inc) for advanced melanoma. Lifileucel is the first tumor-infiltrating lymphocyte therapy, or TIL, approved for solid tumors. Iovance also announced the pricing of a secondary stock offering, which when combined with the approval, led to a huge stock gain. “The approval of Amtagvi […]